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Prostate Cancer (PC) is the worldwide most frequent 
neoplasm among males1, with the highest incidence 
rates in North America, Australia, New Zealand 
and Western Europe2. Most of the cases display a 
slow and asymptomatic growth3,4, and are mainly 
detected at medical routine controls in males over 
65 years5.  Screening programs have been developed 
in order to reduce prostate cancer-specific mortality 
and to enhance patients’ quality of life. However, its 
effectiveness has caused a lot of controversy, and a 
permanent debate within the medical community. In 
this line, different recommendations have been issued 
by medical and government organizations.
The use of prostate-specific antigen as a marker, a 
cornerstone of PC detection during last decades6, has 
remained under discussion due to the uncertainty 
surrounding its benefits, risks and optimal strategy of 
prescription7. On the other hand, screening necessarily 
implies overdiagnosis and overtreatment8, which turn 
into negative aspects when considering that many 
cases of PC will present a low morbidity related to the 
illness and will remain in low grade stages for years9. 
Furthermore, a great proportion of patients suffering 
from the illness will never be diagnosed and will die due 
to another cause3,4.
To date, there is enough evidence that support the 
fact that PC diagnosis is higher in screened patients8-10, 
mainly localized PC and, with a lower proportion, those 
who are in advanced stages. Nevertheless, a Cochrane 
systematic review found that PC screening has not 
reduced global or specific mortality globally8.
Undoubtedly, it is of utmost relevance to optimize 
screening methods in PC. Enhancement of prostate-
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specific antigenusage and the growing evidence 
about recently discovered tumor markers, are 
promissory tools that might decrease the implications 
of overdiagnosis, allowing to distinguish patients with 
asymptomatic PC from those who will need a more 
aggressive management11. Thus, the aftermath derived 
from the curative treatment might be avoided12 when 
taking into account that screening has increased the 
localized PC diagnosis8. Meanwhile, clinical decisions 
should be guided by the best available evidence.
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